ABSTRACT BCG (Glaxo) (0 5 ml =5 X 106 organisms) was given subdermally to 250 patients ten days after resection of a lung carcinoma to stimulate the immune system. Increased activity of lymphocytes and macrophages could possibly result in the destruction of small extrapulmonary tumour deposits that were previously unidentified. The two-year survival of this group of patients was compared with 250 controls not receiving BCG after operation. A comparative analysis of the sex, histological types, and lymph node involvement in relation to the survivals occurring in these two groups showed that the administration of BCG by the method described produced a numerically greater survival rate, which was particularly noticeable in the women. None of these figures, however, is statistically significant. It would be unwise to draw any final conclusion until a five-year survey has been completed.
That some immunological control over the growth of cancer cells in the body might be obtained by increasing the number and activity of lymphocytes and macrophages has been shown from experiments in animals undertaken by many investigators. Various agents-zymosan (Bradner et al 1958) , phytohaemagglutinin (Oppenheim et al, (1965) , Corynebacterium parvum (Halpern et al, 1966) , oestrogen (Biozzi et al, 1957) Bacille Calmette-Guerin (BCG) (Old et al, 1959) , and others-have been shown to be active stimulators for this purpose.
Clearly whatever agent was used it or the stimulated lymphocytes and macrophages had to be carried to the neoplasm by the blood stream. Because of the relative ischaemia of most tumours, the agent or cells could therefore be brought into effective contact with only isolated or small agglomerations of tumour cells. It was thus mandatory that the main mass of tumour should be removed at operation and then the immunostimu- 
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lant agent should be administered to control the growth of isolated non-demonstrable metastases, which would probably have been ultimately responsible for death. In view of the active cellular content of lymph nodes it might be that after operation small deposits left behind in these locations could be more adequately dealt with by the body after the use of an immunostimulant agent.
Of the materials available, BCG seemed to be the most acceptable as a supplement to the surgical resection of carcinoma of the lung. BCG could be given in one dose, and its action could persist for three to four months. It was unlikely to produce any serious side effects, and if it did these could be controlled by isoniazid (INAH). 
Establishment of the trial
To discover the possible effects of giving BCG in the postoperative stages a pilot study was made of 60 consecutive surviving patients who had undergone lung resection by one surgeon between October 1970 and December 1971 and had been given BCG by the method described. The survival rate was compared with the previous 60 consecutive surviving patients, operated on by the same surgeon, who had not received BCG. Two-year and five-year follow-up reports of this series have been published Whitwell, 1974, 1978) . As no serious complication followed the use of this technique, it was considered safe and a larger fully randomised trial was started in December 1971. It was considered that only a large number of cases of resection of lung carcinoma could eliminate those factors that influence small series. In view of the difficulties of assessing and analysing signs and symptoms in the months after operation,' the only feature that would give a factual estimate of the effects of BCG would be the length of survival after operation. The determination of the survival rate at two years and five years after operation in the BCG and the control group was the purpose of this trial. It was not possible to determine the exact cause of death in such a large group of cases, and the death certificate could not be accepted as a reliable explanation of the death of the 'patient. While most patients would die as a direct result of the extension of the malignant disease, quite a number would die of unrelated causes in view of the age of the group. It was assumed that in 500 cases the number would be similar in both groups.
Five hundred consecutive patients who survived resection of a carcinoma of the lung and who were discharged from hospital were selected for this trial. They were all operated on by members of the' surgical staff of the Liverpool Regional Cardiothoracic Surgical Centre. The selection of cases for operation and the operative and postoperative management were similar for all surgeons. It is an agreed policy to undertake resection of the lung for carcinoma only if all macroscopic disease can be extirpated. The presence of affected lymph nodes is not considered a contraindication to resection provided they can be removed. A patient with an oat cell carcinoma diagnosed by bronchoscopic biopsy or sputum cytology was not considered unsuitable for surgery, and was given a preoperative assessment similar to patients with other histological types. "Palliative" resection in the presence of irremovable extension of the tumour or distant metastases is undertaken only in the most exceptional circumstances, and any such cases were not entered into the trial.
Two hundred and fifty patients were to receive BCG in the postoperative phase, and 250 patients were used as a control. The choice of the group in which the patient was to be entered was based on alternation by a disinterested person at the time of registration, which was three days after the operation. In the event 561 patients were registered, of whom 61 were rejected because of death before leaving hospital, change of diagnosis, or nonadministration of BCG.
The BCG was given on the tenth day after the operation, and the patient then attended the routine follow-up in the outpatient department. Adjuvant radiotherapy or chemotherapy was given to those patients who developed a late metastatic lesion causing symptoms.
Any patient who did not leave hospital after operation was rejected from the trial as the cause of death was probably related to the operation rather than the carcinoma.
All resected specimens were submitted to one of three pathologists, and the histological reports used in the trial were those on the resected specimen and the associated lymph nodes.
All patients were registered with the Mersey Regional Cancer Registry who undertake an annual follow-up of all cancer cases. The survival of patients at two years was obtained with the help of this organisation. Five patients were untraceable, two in the control group and three in the BCG group, and these patients were assumed to be dead.
Results Table I  Table 1 shows that the two groups were closely matched as to sex, type of operation, and histological type. Table 2 The overall survival rate at two years was 114/250 nodes and 60-3% of those with negative nodes survived two years, while in the BCG group 34-5% of Table 3 those with positive nodes and 57-7% of those with Comparing the two-year survival rate in the two negative nodes survived two years (X2=1-5).
sexes the number of male survivors was about the same in the two groups-(control 46-1%; BCG Table S 45-6%). There were however more female sur-Analysis of the sex distribution of the two-year vivors in the BCG group (control 43-5%; BCG survival of the positive and negative node groups 56-8%. x2=1-6).
shows that while the male survival rates were similar, there was a contrast, which however was Table 4 not significant, in the survival rate of the women Positive lymph nodes were found in 109 of the with positive nodes when comparing the two control group and 108 of the BCG group (table 4). groups: 47*6% group the total number of survivors who had re-(X2=3-86 with Yates's correction x2=2-68).
ceived BCG (77/152=50-6%) was less than the (P=0'10). controls (83/152=54*6%). The number of women with positive nodes alive at two years was nearly While no results based on survival can be fully Adenocarcinoma-The total survival rate in the accepted until a five-year survey is carried out, BCG group was higher (20/47=42-6%) than in certain observations on the possible effect of BCG the controls (15/51=29.4%) X2= 1-84. All groups on the various histological types can be made as a except women with negative nodes show more surresult of the two-year survey.
vivors when given BCG. Oat cell carcinoma (small cell carcinoma)-The two-year survival rate in all categories of patients with an oat cell carcinoma are similar whether BCG was given or not. It might be expected that in this active form of tumour the speed of cell multiplication would be much greater than could be coped with by cellular immunity, however much it was stimulated. It should be noted, however, that over a quarter of the patients in both groups survived two years (control group 4/15=26.7%, BCG group 6/20=30 0%). While these results are not good they do not justify the pessimism concerning surgery for oat cell carcinoma that has recently developed.
Carcinoma simplex (undifferentiated carcinoma) -The survival rate at two years of the BCG group is considerably better than that of the controls. Carcinoma simplex controls 8/21 _ 38l1% Carcinoma simplex BCG 14/23 60.9% x2=2 3; with Yates's correction x2 = 1 1. This improved survival rate with BCG is reflected throughout all categories of the carcinoma simplex group, and the undifferentiated cell may be more susceptible to cellular immunity.
Mixed cell carcinoma, alveolar cell carcinoma (bronchiolar carcinoma, pulmonary adenomatosis), and clear cell carcinoma-The numbers in these three groups are too small for any discussion.
Although there are trends visible in the response of these different histological types to the administration of BCG, none of the figures are statistically significant. Similar trends were noticeable in our original pilot study at the two-year review, but they became less definite at five years Whitwell, 1974, 1978) . 
